JP7664158B2 - トランスフェリン受容体標的ペプチド - Google Patents

トランスフェリン受容体標的ペプチド Download PDF

Info

Publication number
JP7664158B2
JP7664158B2 JP2021533535A JP2021533535A JP7664158B2 JP 7664158 B2 JP7664158 B2 JP 7664158B2 JP 2021533535 A JP2021533535 A JP 2021533535A JP 2021533535 A JP2021533535 A JP 2021533535A JP 7664158 B2 JP7664158 B2 JP 7664158B2
Authority
JP
Japan
Prior art keywords
seq
peptide
tfr
binding
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021533535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513798A5 (https=
JP2022513798A (ja
JPWO2020124032A5 (https=
Inventor
ザッカリー クルック,
ミ-ヨン ブルスニアック,
ジェイムズ オルソン,
アンドリュー ジェイムズ マイア,
チュンフェン イン,
ジーン グレゴリー ホッピング,
ローランド ストロング,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of JP2022513798A publication Critical patent/JP2022513798A/ja
Publication of JP2022513798A5 publication Critical patent/JP2022513798A5/ja
Publication of JPWO2020124032A5 publication Critical patent/JPWO2020124032A5/ja
Priority to JP2024214382A priority Critical patent/JP2025038018A/ja
Application granted granted Critical
Publication of JP7664158B2 publication Critical patent/JP7664158B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1089Design, preparation, screening or analysis of libraries using computer algorithms
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20Protein or domain folding
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pain & Pain Management (AREA)
JP2021533535A 2018-12-14 2019-12-13 トランスフェリン受容体標的ペプチド Active JP7664158B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024214382A JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779885P 2018-12-14 2018-12-14
US62/779,885 2018-12-14
US201962836520P 2019-04-19 2019-04-19
US62/836,520 2019-04-19
PCT/US2019/066376 WO2020124032A1 (en) 2018-12-14 2019-12-13 Transferrin receptor targeting peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024214382A Division JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Publications (4)

Publication Number Publication Date
JP2022513798A JP2022513798A (ja) 2022-02-09
JP2022513798A5 JP2022513798A5 (https=) 2022-12-20
JPWO2020124032A5 JPWO2020124032A5 (https=) 2022-12-20
JP7664158B2 true JP7664158B2 (ja) 2025-04-17

Family

ID=71077078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533535A Active JP7664158B2 (ja) 2018-12-14 2019-12-13 トランスフェリン受容体標的ペプチド
JP2024214382A Pending JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024214382A Pending JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Country Status (8)

Country Link
US (1) US20220048961A1 (https=)
EP (1) EP3893913B1 (https=)
JP (2) JP7664158B2 (https=)
CN (1) CN113329758A (https=)
AU (1) AU2019398467A1 (https=)
CA (1) CA3120466A1 (https=)
IL (1) IL283839A (https=)
WO (1) WO2020124032A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
CN111647048B (zh) * 2020-06-22 2021-04-02 中国科学院昆明动物研究所 干扰多肽在制备抗SARS-CoV-2药物中的应用
US12076364B2 (en) 2020-06-22 2024-09-03 Kunming Institute Of Zoology, Chinese Academy Of Sciences Use of interference peptide in preparation of anti-SARS-CoV-2 medicament
JP2022014707A (ja) * 2020-07-07 2022-01-20 東亞合成株式会社 キャリアペプチドフラグメントおよびその利用
CN116075524A (zh) * 2020-07-30 2023-05-05 华盛顿大学 转铁蛋白受体结合蛋白
AU2021386254A1 (en) * 2020-11-30 2023-06-29 Blaze Bioscience, Inc. Compositions and methods for selective depletion of target molecules
WO2022180628A1 (en) * 2021-02-23 2022-09-01 Ichilov Tech Ltd. Fusion proteins for treating cns diseases
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023023031A2 (en) * 2021-08-17 2023-02-23 Blaze Bioscience, Inc. Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof
JPWO2023022234A1 (https=) * 2021-08-19 2023-02-23
CN118556069A (zh) * 2021-10-01 2024-08-27 首尔大学校产学协力团 用于穿透血脑屏障的肽及其用途
CN118139896A (zh) * 2021-10-15 2024-06-04 南通壹宸生物医药科技有限公司 一种双特异性结合分子
CN115160408B (zh) * 2022-06-29 2025-04-22 辽宁天增祥生物科技有限公司 降压肽或中国蛤蜊降压肽提取物及其应用
CN115925981B (zh) * 2022-08-18 2025-05-23 河南工业大学 一种特异性靶向革兰氏阴性菌的抗菌肽及其应用
EP4626906A1 (en) * 2022-11-29 2025-10-08 Vacino Biotech Co., Ltd. Transporter peptides and application thereof
TW202434613A (zh) * 2023-02-17 2024-09-01 日商肽夢想股份有限公司 人類運鐵蛋白受體結合肽
WO2024238304A2 (en) * 2023-05-12 2024-11-21 University Of Washington Improved transferrin receptor binding proteins
AU2024329222A1 (en) * 2023-08-18 2026-02-12 Eli Lilly And Company Engineered transferrin receptor binding peptides as well as methods of making and using the same
CN119896743B (zh) * 2023-10-26 2025-09-26 华南理工大学 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用
WO2025090121A1 (en) * 2023-10-27 2025-05-01 Yale University Conjugate and methods of treatment
WO2025096245A1 (en) * 2023-11-02 2025-05-08 The Regents Of The University Of California Design rules for endosomal escape
CN120647772A (zh) * 2024-03-15 2025-09-16 迦进生物医药(上海)有限公司 特异性结合转铁蛋白受体的多肽及其应用
CN120459270A (zh) * 2025-05-16 2025-08-12 中国人民解放军海军军医大学 OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157330A1 (en) 2003-01-09 2004-08-12 Arizeke Pharmaceuticals, Inc. Compositions and methods for targeted biological delivery of molecular carriers
WO2018031424A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743893B2 (en) * 2000-11-30 2004-06-01 The Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
US7973019B1 (en) * 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
CA2864126A1 (en) * 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
AU2013266611B2 (en) * 2012-05-21 2016-08-11 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
CN103897033A (zh) * 2014-03-31 2014-07-02 中国药科大学 转铁蛋白受体TfR特异性结合肽及其应用
WO2016077840A2 (en) * 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
MX391086B (es) * 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157330A1 (en) 2003-01-09 2004-08-12 Arizeke Pharmaceuticals, Inc. Compositions and methods for targeted biological delivery of molecular carriers
WO2018031424A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Also Published As

Publication number Publication date
JP2022513798A (ja) 2022-02-09
JP2025038018A (ja) 2025-03-18
EP3893913A1 (en) 2021-10-20
WO2020124032A1 (en) 2020-06-18
AU2019398467A1 (en) 2021-06-24
CN113329758A (zh) 2021-08-31
US20220048961A1 (en) 2022-02-17
EP3893913B1 (en) 2025-03-26
CA3120466A1 (en) 2020-06-18
IL283839A (en) 2021-07-29
EP3893913A4 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
JP7664158B2 (ja) トランスフェリン受容体標的ペプチド
US20230151068A1 (en) Peptide compositions and methods of use thereof for disrupting tead interactions
JP7564143B2 (ja) Xten共役組成物およびそれを製造する方法
US11331393B2 (en) Renal-homing peptide conjugates and methods of use thereof
JP7280193B2 (ja) 軟骨ホーミングペプチドコンジュゲート及びその使用方法
US20250326866A1 (en) Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof
HK1198173A1 (en) Potent and selective inhibitors of nav1.3 and nav1.7
US12528846B2 (en) BH4 stabilized peptides and uses thereof
CN117615774A (zh) Pd-l1结合肽和肽复合物及其使用方法

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250407

R150 Certificate of patent or registration of utility model

Ref document number: 7664158

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150